Taiyen Biotech Co Stock Current Asset
| 1737 Stock | TWD 32.20 0.05 0.16% |
Taiyen Biotech Co fundamentals help investors to digest information that contributes to Taiyen Biotech's financial success or failures. It also enables traders to predict the movement of Taiyen Stock. The fundamental analysis module provides a way to measure Taiyen Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taiyen Biotech stock.
Taiyen |
Taiyen Biotech Co Company Current Asset Analysis
Taiyen Biotech's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Taiyen Biotech Current Asset | 2.48 B |
Most of Taiyen Biotech's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taiyen Biotech Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Taiyen Biotech Co has a Current Asset of 2.48 B. This is 65.34% lower than that of the Food Products sector and 30.81% lower than that of the Consumer Staples industry. The current asset for all Taiwan stocks is 73.39% higher than that of the company.
Taiyen Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taiyen Biotech's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taiyen Biotech could also be used in its relative valuation, which is a method of valuing Taiyen Biotech by comparing valuation metrics of similar companies.Taiyen Biotech is currently under evaluation in current asset category among its peers.
Taiyen Fundamentals
| Return On Equity | 0.0642 | |||
| Return On Asset | 0.0346 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 4.82 B | |||
| Shares Outstanding | 200 M | |||
| Shares Owned By Insiders | 48.28 % | |||
| Shares Owned By Institutions | 5.34 % | |||
| Price To Earning | 14.76 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 1.61 X | |||
| Revenue | 4.1 B | |||
| Gross Profit | 1.37 B | |||
| EBITDA | 705.52 M | |||
| Net Income | 393.23 M | |||
| Cash And Equivalents | 2.14 B | |||
| Cash Per Share | 10.69 X | |||
| Total Debt | 53.08 M | |||
| Debt To Equity | 2.00 % | |||
| Current Ratio | 5.41 X | |||
| Book Value Per Share | 31.99 X | |||
| Cash Flow From Operations | 600.08 M | |||
| Earnings Per Share | 2.09 X | |||
| Number Of Employees | 33 | |||
| Beta | 0.22 | |||
| Market Capitalization | 6.53 B | |||
| Total Asset | 8.47 B | |||
| Retained Earnings | 1.46 B | |||
| Working Capital | 2.08 B | |||
| Current Asset | 2.48 B | |||
| Current Liabilities | 410 M | |||
| Z Score | 73.8 | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 3.82 % | |||
| Net Asset | 8.47 B | |||
| Last Dividend Paid | 1.5 |
About Taiyen Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taiyen Biotech Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taiyen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taiyen Biotech Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Taiyen Stock Analysis
When running Taiyen Biotech's price analysis, check to measure Taiyen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taiyen Biotech is operating at the current time. Most of Taiyen Biotech's value examination focuses on studying past and present price action to predict the probability of Taiyen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taiyen Biotech's price. Additionally, you may evaluate how the addition of Taiyen Biotech to your portfolios can decrease your overall portfolio volatility.